News

Virginia Catalyst Awards $1.9 Million in Grants to Support Life Sciences in the Commonwealth

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC),  announced that it has awarded $1.9 million in grants to three life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 12 of Virginia Catalyst’s ongoing mission to stimulate economic development by promoting collaborative projects that address large, unmet needs for improving human health, and that can create high-paying jobs in the Commonwealth.

“We are excited to continue our mission of supporting collaborations and fostering economic growth in Virginia’s life sciences, enabling the Commonwealth to compete on a national and global scale,” said Mike Grisham, CEO, Virginia Catalyst. “The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the Commonwealth.”

Through this 12th round of funding, Virginia Catalyst has awarded 49 grants totaling $24 million, resulting in over $44 million in matching funds and an additional $250 million in follow-on funding to date.

The awards, which range from $200,000 to $800,000, help fund collaborative efforts between industry and Virginia research universities with the goal of:

  • Funding innovative, collaborative, translational research projects that elevate the level of sponsored research at Virginia’s universities and have the potential to significantly improve human health and create high value jobs in the Commonwealth
  • Accelerating commercialization of Virginia research university inventions and discoveries and to achieve competitive critical mass through robust collaborations of Virginia research universities and industry

Grant Round 12 project awardees:

Project: Optimization and commercialization of environmentally-sustainable biofungicides

  • Company: AgroSpheres, Inc. (Charlottesville, VA)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $600,000

Project: Design automation for scaled manufacturing of advanced custom orthopedic braces

  • Company: Icarus Medical Innovations (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $600,000

Project: Pilot study to evaluate a nonsurgical gel patch for eardrum repair in human patients

  • University collaborators: Eastern Virginia Medical School and Virginia Commonwealth University
  • Funding amount: $737,369

Recent News

02/09/2026

Activation Capital Expands Frontier BioHealth and Strengthens its Continuum of Support for Life Sciences Founders

Activation Capital today announced enhancements to Frontier BioHealth, building on the program’s successful 2024 launch and inaugural cohort while reinforcing its broader continuum of life sciences entrepreneurship programs designed to help science-driven companies progress toward commercialization and investor readiness. Frontier BioHealth was created to address a critical gap facing emerging biohealth founders: access to practical

02/04/2026

Governor Spanberger Announces Expansion of Paid Internship Opportunities with Virginia Businesses

Governor Abigail Spanberger today launched InternshipsVA, a new statewide program to help Virginia employers design and launch high-quality, paid internships for higher education students in Virginia. The Commonwealth has committed $14.5 million each year to support this program. The Governor was joined by leaders of the Virginia Chamber of Commerce, the Virginia Economic Development Partnership

02/03/2026

SSI Diagnostica Group Acquires InDevR

SSI Diagnostica Group, a global company specializing in testing solutions for infectious diseases, has announced the acquisition of InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The addition strengthens SSID Group’s leadership in pneumococcal vaccine QC testing with next-generation multiplexing assays and enhanced customization capabilities. InDevR will advance the Group’s offering by